新生儿抗菌药物管理项目:一项Meta分析
该Meta分析纳入70项研究、超过35万新生儿,评估新生儿抗菌药物管理项目(ASP)的成分及其对临床结局、成本效益和耐药性的影响。中等确定性证据显示ASP干预显著减少NICU及产后病房抗菌药物启动率、疗程和超过5天的使用,低确定性证据提示降低经济负担和耐药性且不增加败血症相关死亡率。
要点
- 新生儿ASP可显著降低NICU抗菌药物启动率(合并RD 19%,95%CI 14%-24%)。
- ASP与缩短抗菌药物疗程(合并RD 20%,95%CI 10%-30%)和住院时长相关。
- 低确定性证据提示ASP降低经济负担和耐药性,不增加败血症死亡率。
核心结论
- 中等至低确定性证据表明新生儿ASP干预与减少抗菌药物启动和疗程相关,且不增加不良事件。
研究设计与样本
- 系统检索PubMed、Medline、Embase、Cochrane CENTRAL、Web of Science和SCOPUS截至2023年5月22日,纳入随机和非随机试验、观察性及质量改进研究,共70项研究(44项队列和26项观察性研究)超过35万新生儿。
主要发现
- 使用抗菌药物超过5天的合并RD为9%(95%CI 3%至15%;5项研究,9412名婴儿)。
临床怎么用
- 新生儿病房可考虑实施ASP干预以减少不必要的抗菌药物启动和缩短疗程。
- ASP实施需关注干预措施、人群设置和结局定义的异质性。
局限性
- 研究间存在显著异质性,ASP干预措施、人群设置和结局定义差异较大。
- 关于经济负担和耐药性降低的证据确定性较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Neonatal sepsis is a significant contributor to mortality and morbidity; however, the uncontrolled use of antimicrobials is associated with significant adverse effects. Our objective with this article is to review the components of neonatal antimicrobial stewardship programs (ASP) and their effects on clinical outcomes, cost-effectiveness, and antimicrobial resistance. METHODS: We selected randomized and nonrandomized trials and observational and quality improvement studies evaluating the impact of ASP with a cutoff date of May 22, 2023. The data sources for these studies included PubMed, Medline, Embase, Cochrane CENTRAL, Web of Science, and SCOPUS. Details of the ASP components and clinical outcomes were extracted into a predefined form. RESULTS: Of the 4048 studies retrieved, 70 studies (44 cohort and 26 observational studies) of >350 000 neonates met the inclusion criteria. Moderate-certainty evidence reveals a significant reduction in antimicrobial initiation in NICU (pooled risk difference [RD] 19%; 95% confidence interval [CI] 14% to 24%; 21 studies, 27 075 infants) and combined NICU and postnatal ward settings (pooled RD 8%; 95% CI 6% to 10%; 12 studies, 358 317 infants), duration of antimicrobial agents therapy (pooled RD 20%; 95% CI 10% to 30%; 9 studies, 303 604 infants), length of therapy (pooled RD 1.82 days; 95% CI 1.09 to 2.56 days; 10 studies, 157 553 infants), and use of antimicrobial agents >5 days (pooled RD 9%; 95% CI 3% to 15%; 5 studies, 9412 infants). Low-certainty evidence reveals a reduction in economic burden and drug resistance, favorable sustainability metrices, without an increase in sepsis-related mortality or the reinitiation of antimicrobial agents. Studies had heterogeneity with significant variations in ASP interventions, population settings, and outcome definitions. CONCLUSIONS: Moderate- to low-certainty evidence reveals that neonatal ASP interventions are associated with reduction in the initiation and duration of antimicrobial use, without an increase in adverse events.
引用
- Mascarenhas D, Ho MSP, Ting J, et al. Antimicrobial Stewardship Programs in Neonates: A Meta-Analysis. Pediatrics. 2024. PMID: 38766702. doi:10.1542/peds.2023-065091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。